X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (187726) 187726
Journal Article (134486) 134486
Newspaper Article (6631) 6631
Newsletter (2620) 2620
Book Chapter (720) 720
Book / eBook (353) 353
Magazine Article (332) 332
Dissertation (187) 187
Web Resource (137) 137
Conference Proceeding (102) 102
Trade Publication Article (87) 87
Transcript (57) 57
Publication (53) 53
Government Document (46) 46
Book Review (15) 15
Reference (12) 12
Report (6) 6
Streaming Video (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
peptides (235405) 235405
chemistry (191769) 191769
organic chemistry (189662) 189662
metallurgy (187726) 187726
human necessities (179772) 179772
hygiene (179135) 179135
medical or veterinary science (179110) 179110
preparations for medical, dental, or toilet purposes (173695) 173695
specific therapeutic activity of chemical compounds ormedicinal preparations (158209) 158209
biochemistry (110718) 110718
microbiology (109864) 109864
enzymology (105488) 105488
beer (105254) 105254
wine (105251) 105251
vinegar (105237) 105237
spirits (105236) 105236
mutation or genetic engineering (105235) 105235
culture media (97415) 97415
compositions thereof (97240) 97240
microorganisms or enzymes (97240) 97240
propagating, preserving or maintaining microorganisms (97240) 97240
humans (79658) 79658
animals (55342) 55342
physics (49772) 49772
testing (49154) 49154
measuring (48966) 48966
investigating or analysing materials by determining theirchemical or physical properties (48826) 48826
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (44209) 44209
male (36938) 36938
female (32186) 32186
compositions or test papers therefor (28495) 28495
condition-responsive control in microbiological orenzymological processes (28495) 28495
measuring or testing processes involving enzymes, nucleicacids or microorganisms (28495) 28495
processes of preparing such compositions (28495) 28495
mice (24642) 24642
proteins (23305) 23305
middle aged (17064) 17064
processes using microorganisms (16287) 16287
pharmacology & pharmacy (16241) 16241
research (14479) 14479
biochemistry & molecular biology (14151) 14151
adult (13388) 13388
rats (13386) 13386
nucleic acids (13196) 13196
analysis (13195) 13195
derivatives thereof (12927) 12927
aged (12732) 12732
sugars (12645) 12645
nucleotides (12628) 12628
nucleosides (12482) 12482
cancer (11897) 11897
immunology (11521) 11521
heterocyclic compounds (11325) 11325
expression (11198) 11198
medicine (10916) 10916
lipids (10767) 10767
research article (10725) 10725
neurosciences (10706) 10706
agriculture (10644) 10644
forestry (10471) 10471
fishing (10460) 10460
hunting (10451) 10451
trapping (10451) 10451
animal husbandry (10447) 10447
health aspects (10357) 10357
multidisciplinary sciences (9987) 9987
cell biology (9657) 9657
oncology (8965) 8965
gene expression (8629) 8629
inflammation (8518) 8518
care and treatment (8422) 8422
medicine, research & experimental (8386) 8386
disease models, animal (8252) 8252
physiological aspects (8153) 8153
amino acid sequence (7961) 7961
care of birds, fishes, insects (7902) 7902
new breeds of animals (7902) 7902
rearing or breeding animals, not otherwise provided for (7902) 7902
apoptosis (7865) 7865
rodents (7829) 7829
science (7733) 7733
peptide (7631) 7631
endocrinology & metabolism (7267) 7267
alzheimer's disease (7256) 7256
diabetes (7005) 7005
cell line, tumor (6999) 6999
treatment outcome (6978) 6978
biology (6775) 6775
enzymes (6773) 6773
studies (6702) 6702
mice, inbred c57bl (6448) 6448
peptides - therapeutic use (6296) 6296
peptides - chemistry (6276) 6276
molecular sequence data (6099) 6099
in-vitro (6036) 6036
activation (6000) 6000
disease (5979) 5979
cells (5957) 5957
signal transduction (5921) 5921
in-vivo (5864) 5864
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (163) 163
Online Resources - Online (40) 40
UofT at Mississauga - Stacks (36) 36
Collection Dvlpm't (Acquisitions) - Vendor file (34) 34
Chemistry (A D Allen) - Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Closed Orders (13) 13
Engineering & Comp. Sci. - Stacks (4) 4
UofT at Scarborough - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Aerospace - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Missing (1) 1
Gerstein Science - Periodical Stacks (1) 1
Robarts - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (304730) 304730
French (63576) 63576
German (33105) 33105
Chinese (12155) 12155
Japanese (7291) 7291
Spanish (6665) 6665
Korean (5119) 5119
Portuguese (3646) 3646
Russian (3155) 3155
Danish (2133) 2133
Norwegian (1415) 1415
Polish (1395) 1395
Hungarian (1056) 1056
Finnish (1029) 1029
Czech (813) 813
Slovenian (684) 684
Swedish (645) 645
Hebrew (639) 639
Croatian (373) 373
Slovak (337) 337
Ukrainian (319) 319
Greek (315) 315
Serbian (279) 279
Italian (271) 271
Lithuanian (249) 249
Turkish (193) 193
Bulgarian (178) 178
Estonian (145) 145
Dutch (138) 138
Icelandic (96) 96
Arabic (59) 59
Romanian (58) 58
Indonesian (47) 47
Latvian (32) 32
Bosnian (10) 10
Hindi (1) 1
Persian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Postgraduate Medical Journal, ISSN 0032-5473, 12/2016, Volume 92, Issue 1094, pp. 726 - 734
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | METAANALYSIS | RANDOMIZED-TRIAL | IN-HOSPITAL MORTALITY | DYSFUNCTION | NATRIURETIC PEPTIDE | COMBINATION | EPIDEMIOLOGY | ROSUVASTATIN | URODILATIN | Vasodilator Agents - therapeutic use | Erythropoietin - therapeutic use | United States | Humans | Calcium Channel Blockers - therapeutic use | Heart Failure - physiopathology | Aminobutyrates - therapeutic use | Cardiotonic Agents - therapeutic use | Societies, Medical | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Isosorbide Dinitrate - therapeutic use | Cardiology | Platelet Aggregation Inhibitors - therapeutic use | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Hematinics - therapeutic use | Fumarates - therapeutic use | Anticoagulants - therapeutic use | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | American Heart Association | Stroke Volume | Cardiovascular Agents - therapeutic use | Hydralazine - therapeutic use | Atrial Natriuretic Factor - therapeutic use | Iron - therapeutic use | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Peptide Fragments - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Practice Guidelines as Topic | Heart failure | Care and treatment | Usage | Analysis | Americans | Diagnosis | Cardiac output | Health aspects | Evidence-based medicine
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
...) as an important negative prognostic biomarker Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counter-intuitive that this chemokine correlates with therapeutic... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
2006, 2nd ed., ISBN 0849316308, 354
There are more than 500 biopharmaceuticals on the market, including more than 200 therapeutic proteins, making biologics the fastest growing sector in the biopharmaceutical market... 
Proteins | Drug Administration Routes | Peptides | therapeutic use | Protein drugs | pharmacology
Book
2002, Volume 16, Issue 3, 18
... have led to a variety of evaluable therapeutic approaches in MS. However, in contrast to the successfully introduced and established immunomodulatory therapies (e.g... 
Lenercept, therapeutic use | Monoclonal antibodies, therapeutic use | Tumour necrosis factor antagonists, therapeutic us | Cetermin, therapeutic use | Sulfasalazine, therapeutic use | Cladribine, therapeutic use | Research and development | Interleukin 10, therapeutic use | Infliximab, therapeutic use | Muromonab CD3, therapeutic use | Gusperimus, therapeutic use | Priliximab, therapeutic use | Multiple sclerosis, treatment | Immunoglobulins, therapeutic use | Interleukin 4, therapeutic use | Roquinimex, therapeutic use | AI 100, therapeutic use | Antibodies | Pharmacotherapy | Cancer Research | Molecular Medicine | Biomedicine | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | ALTERED PEPTIDE LIGAND | SECONDARY PROGRESSIVE MS | T-CELL VACCINATION | IMMUNOLOGY | FACTOR-ALPHA | TUMOR-NECROSIS-FACTOR | GROWTH-FACTOR-BETA | ONCOLOGY | INTRAVENOUS IMMUNOGLOBULIN | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | Antigens, CD - immunology | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Multiple Sclerosis - therapy | Antigens - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Treatment Failure | Multiple Sclerosis - immunology | Multiple Sclerosis - pathology | T-Lymphocytes - immunology | Photopheresis | Clinical Trials as Topic - methods | Cytokines - antagonists & inhibitors
Book Review
Nucleic acids research, ISSN 1362-4962, 2016, Volume 44, Issue 14, pp. 6518 - 6548
Journal Article
Drugs, ISSN 0012-6667, 07/2000, Volume 60, Issue 1, pp. 95 - 113
... (non-insulin-dependent) diabetes mellitus. The aim of this article is to briefly review the various therapeutic agents available for management of patients with type 2 diabetes mellitus and to suggest a potential approach to drug selection... 
Tolazamide, therapeutic use | Alpha glucosidase inhibitors, therapeutic use | Amylin agonists, therapeutic use | Acetohexamide, therapeutic use | Chlorpropamide, therapeutic use | Biguanides, therapeutic use | Tolbutamide, therapeutic use | Gliquidone, therapeutic use | Meglitinide, therapeutic use | Insulins, therapeutic use | Research and development | Glimepiride, therapeutic use | Type 2 diabetes mellitus, treatment | Glibenclamide, therapeutic use | Thiazolidinediones, therapeutic use | Sulphonylureas, therapeutic use | Gliclazide, therapeutic use | Glipizide, therapeutic use | Glucagon like peptide 1, therapeutic use | Antihyperglycaemics, therapeutic use | Insulin, therapeutic use | Insulin glargine, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | ACTING INSULIN ANALOG | MIDDLE-AGED MEN | HUMAN AMYLIN ANALOG | PHARMACOLOGY & PHARMACY | TOXICOLOGY | IMPROVED GLYCEMIC CONTROL | PLACEBO-CONTROLLED TRIAL | DOUBLE-BLIND CROSSOVER | ALPHA-GLUCOSIDASE INHIBITION | HEART-DISEASE MORTALITY | MYOCARDIAL-INFARCTION DIGAMI | ORAL ANTIDIABETIC AGENTS | Hypoglycemic Agents - therapeutic use | Insulin - pharmacology | Diabetes Mellitus, Type 2 - physiopathology | Humans | Diabetes Mellitus, Type 2 - drug therapy | Forecasting | Insulin - therapeutic use | Hypoglycemic Agents - pharmacology
Journal Article